Journal
REPRODUCTIVE HEALTH MATTERS
Volume 9, Issue 18, Pages 44-48Publisher
BLACKWELL SCIENCE LTD
DOI: 10.1016/S0968-8080(01)90089-8
Keywords
breast cancer; genetic testing; risk assessment; advertising; USA
Categories
Ask authors/readers for more resources
This article critiques on advertisement in a theatre playbill by a bio-technology company for its commercial test for the BRCA1 and BRCA2 genetic mutation, which may indicate a higher risk for breast and ovarian cancer. The advertisement targets a vulnerable audience attending a play about one woman's isolated and painful death from ovarian cancer. It promotes a product with incomplete and at times incorrect information, and it misguides women by suggesting that they contact the company directly about this test, rather than encouraging them to talk to their health core providers about genetic testing and their personal risk of breast cancer. In on era in which more genetic tests will be integrated into clinical practice, we con expect on increase in direct-to-consumer marketing for such tests. This advertisement is on example of what we need to be on guard against.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available